← United States · Coverage record
US · SEC FORM 4
Repare Therapeutics Inc.
RPTX · — · CIK 0001808158 · Healthcare
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
0 Form 4 transaction lines observed in the same window
0 sales · 0 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
No Form 4 transaction event is present in the current 180-day window.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2023-11-16 · BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
The FINRA report lists no short interest for this ticker.
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2023-11-16 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Shares, no par value | 295,745 | USD 5.38 | USD 1,591,108 | SEC filing ↗ |
| 2023-11-15 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Shares, no par value | 931,556 | USD 5.00 | USD 4,657,780 | SEC filing ↗ |
| 2023-11-02 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Shares, no par value | 783,709 | USD 3.60 | USD 2,821,352 | SEC filing ↗ |
| 2022-06-13 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Shares, no par value | 149,161 | USD 12.73 | USD 1,898,820 | SEC filing ↗ |
| 2022-06-06 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Shares, no par value | 6,869 | USD 13.21 | USD 90,739 | SEC filing ↗ |
| 2022-06-03 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Shares, no par value | 644,044 | USD 12.29 | USD 7,915,301 | SEC filing ↗ |
| 2022-06-02 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Shares, no par value | 1,186,045 | USD 11.68 | USD 13,853,006 | SEC filing ↗ |
| 2022-05-18 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Shares, no par value | 420,000 | USD 8.50 | USD 3,570,000 | SEC filing ↗ |
| 2022-01-19 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Shares, no par value | 997,961 | USD 14.10 | USD 14,071,250 | SEC filing ↗ |
| 2021-11-16 | Civik Thomas | Purchase (P) | Common Shares | 7,500 | USD 28.08 | USD 210,600 | SEC filing ↗ |
| 2020-06-23 | Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P. | Purchase (P) | Common Shares | 250,000 | USD 20.00 | USD 5,000,000 | SEC filing ↗ |
| 2020-06-23 | Versant Affiliates Fund V, L.P.; Versant Ophthalmic Affiliates I, L.P.; Versant Venture Capital V (Canada), LP; Versant Venture Capital V, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures V (Canada), L.P.; Versant Ventures V GP-GP (Canada), Inc.; Versant Ventures V, LLC; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC | Purchase (P) | Common Shares | 250,000 | USD 20.00 | USD 5,000,000 | SEC filing ↗ |
| 2020-06-23 | Segal Lloyd Mitchell | Purchase (P) | Common Stock | 5,000 | USD 20.00 | USD 100,000 | SEC filing ↗ |
| 2020-06-23 | SCHAFER CAROL | Purchase (P) | Common Shares | 8,000 | USD 20.00 | USD 160,000 | SEC filing ↗ |
| 2020-06-23 | RHOADS ANN D | Purchase (P) | Common Shares | 4,000 | USD 20.00 | USD 80,000 | SEC filing ↗ |
Form 4 evidence
8 transaction lines in the latest 365-day window; 585 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-01-28 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | U (U) | Common Shares, no par value | 10,166,943 | USD — | USD — | SEC filing ↗ |
| 2026-01-28 | SCHAFER CAROL | D (D) | Common Shares | 8,000 | USD — | USD — | SEC filing ↗ |
| 2026-01-28 | RHOADS ANN D | D (D) | Common Shares | 4,000 | USD — | USD — | SEC filing ↗ |
Show recent Form 4 evidence (6 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-01-28 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | U (U) | Common Shares, no par value | 10,166,943 | USD — | USD — | SEC filing ↗ |
| 2026-01-28 | SCHAFER CAROL | D (D) | Common Shares | 8,000 | USD — | USD — | SEC filing ↗ |
| 2026-01-28 | RHOADS ANN D | D (D) | Common Shares | 4,000 | USD — | USD — | SEC filing ↗ |
| 2026-01-28 | Forte Steve | D (D) | Common Shares | 56,786 | USD — | USD — | SEC filing ↗ |
| 2026-01-28 | Civik Thomas | D (D) | Common Shares | 7,500 | USD — | USD — | SEC filing ↗ |
| 2026-01-28 | Alves Sandra Isabelle Barros | D (D) | Common Shares | 31,622 | USD — | USD — | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | RPTX |
| CIK | 0001808158 |
| Sector | Healthcare |
| Industry | — Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | — |
Data coverage
| Local Form 4 history | 585 transaction lines from 2020-06-23 to 2026-01-28 46 P purchase lines · 232 S sale lines · 307 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.